目的 探究苦參膠囊聯(lián)合柳氮磺吡啶治療潰瘍性結(jié)腸炎的臨床效果。方法 選取2019年6月—2021年2月渭南市中心醫(yī)院收治的122例潰瘍性結(jié)腸炎患者，根據(jù)隨機(jī)數(shù)字表法分為對照組和治療組，每組各61例。對照組口服柳氮磺吡啶腸溶片，1g/次，3次/d。治療組在對照組基礎(chǔ)上口服苦參膠囊，4～6粒/次，3次/d。兩組患者治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者內(nèi)鏡評分和Sutherland疾病活動指數(shù)（DAI）評分，血清白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）、血沉（ESR）和白細(xì)胞介素-10（IL-10）水平，及血清低氧誘導(dǎo)因子-1α（HIF-1α）和Toll樣受體4（TLR4）水平。結(jié)果 治療后，治療組總有效率（93.44%）明顯高于對照組（80.33%，P<0.05）。治療后，兩組內(nèi)鏡評分和DAI評分均明顯降低（P<0.05），且治療后明顯低于對照組（P<0.05）。治療后，兩組血清IL-6、TNF-α、CRP及ESR水平均明顯下降，而IL-10水平明顯升高（P<0.05），且治療組血清水平明顯好于對照組（P<0.05）。治療后，兩組血清HIF-1α、TLR4水平均明顯下降（P<0.05），且治療組明顯低于對照組（P<0.05）。結(jié)論 苦參膠囊聯(lián)合柳氮磺吡啶治療潰瘍性結(jié)腸炎患者效果顯著，可調(diào)節(jié)血清HIF-1α、TLR4水平，改善癥狀，緩解機(jī)體炎癥，且安全性高。

Objective To explore the clinical effect of Kushen Capsules combined with sulfasalazine in treatment of ulcerative colitis. Methods Patients (122 cases) with ulcerative colitis in Weinan Central Hospital from June 2019 to February 2021 were prospectively selected and divided into control and treatment group, and each group had 61 cases by the random number table method. Patients in the control group were po administered with Sulfasalazine Enteric-Coated Tablets, 1 g/time, three times daily. Patients in the treatment group were po administered with Kushen Capsules on the basis of the control group, 4 — 6 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluation was evaluated, the endoscopic and DAI scores, serum levels of IL-6, TNF-α, CRP, ESR, IL-10, HIF-1α, and TLR4 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (93.44%) was significantly higher than that of the control group (80.33%, P < 0.05). After treatment, the endoscopic score and DAI score in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those of the control group (P < 0.05). After treatment, the serum levels of IL-6, TNF-α, CRP and ESR in two groups were significantly decreased, while the level of IL-10 were significantly increased (P < 0.05), and the serum level in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of serum HIF-1α and TLR4 in two groups were significantly decreased (P < 0.05), and those in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusions Kushen Capsules combined with sulfasalazine has a significant effect in the treatment of ulcerative colitis, can adjust serum HIF-1α and TLR4 levels, promote symptom improvement, relieve inflammation, and has high safety.

R975

陜西省重點(diǎn)研發(fā)計(jì)劃項(xiàng)目（2019SF-293）